Amol Akhade/hiranandanihospital.org
Aug 18, 2025, 11:18
Amol Akhade: Trials to Watch – WCLC 2025
Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“Trials to Watch – WCLC 2025
Plenary LBAs:
FLAURA2: Osimertinib + Chemo (OS update)
Aumolertinib + Chemo (EGFRm NSCLC)
HARMONi-A: Ivonescimab + Chemo vs Chemo
ARROS-1: Zidesamtinib (ROS1+)
CheckMate 816: Neoadjuvant Nivolumab (OS)
EA5181: Durvalumab + CRT in Stage III
NADIM Adjuvant: Nivolumab + Chemo
Oncology is moving fast—practice-changing data ahead!”
Drew Moghanaki, Chief Medical Officer at Respirati, shared a post by Amol Akhade, adding:
“EA5181: a phase III RCT comparing concurrent CRT+Durva vs PACIFIC for clinical stage III NSCLC. Thank you Nathan A. Pennell and John Varlotto for your stalwart leadership completing this NCI sponsored study.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 13:06
Aug 18, 2025, 13:03
Aug 18, 2025, 12:53
Aug 18, 2025, 12:52
Aug 18, 2025, 12:44
Aug 18, 2025, 12:09
Aug 18, 2025, 11:58
Aug 18, 2025, 11:52
Aug 18, 2025, 11:28
Aug 18, 2025, 11:24